Efficacy of Providing the PI3K p110α Inhibitor BYL719 (Alpelisib) to Middle-Aged Mice in Their Diet

BYL719 (alpelisib) is a small molecule inhibitor of PI3K p110α developed for cancer therapy. Targeted suppression of PI3K has led to lifespan extension in rodents and model organisms. If PI3K inhibitors are to be considered as an aging therapeutic, it is important to understand the potential consequ...

Descripción completa

Detalles Bibliográficos
Autores principales: Hedges, Christopher P., Boix, Jordi, Jaiswal, Jagdish K., Shetty, Bhoopika, Shepherd, Peter R., Merry, Troy L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7911305/
https://www.ncbi.nlm.nih.gov/pubmed/33503847
http://dx.doi.org/10.3390/biom11020150

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7911305/
https://www.ncbi.nlm.nih.gov/pubmed/33503847
http://dx.doi.org/10.3390/biom11020150

Ejemplares similares